•Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores
•Caution in Handling Switchers in Pharmacoepidemiologic Studies Estimating Treatment Effects: The Example of Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease
•Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease
•Oral FPR2/ALX modulators tune myeloid cell activity to ameliorate mucosal inflammation in inflammatory bowel disease
•Comparative efficacy and safety of vedolizumab and antitumor necrosis factor alfa in patients with inflammatory bowel diseases: A meta-analysis